サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1380440

バーチャル臨床試験の世界市場：2023～2030年

Global Virtual Clinical Trials Market 2023-2030

出版日
ページ情報
英文 120 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
バーチャル臨床試験の世界市場：2023～2030年
出版日: 2023年09月30日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバーチャル臨床試験市場は、予測期間中にCAGR 8.5%の大幅な成長が見込まれています。研究開発活動の活発化、医療のデジタル化の進展、テレヘルスの導入などが世界市場の成長を促す主な要因となっています。臨床研究機関、製薬会社、バイオテクノロジー企業間の提携や、政府の結束した取り組みが、市場開拓にさらに貢献しています。

2020年4月に発表されたcontinuum clinical reportによると、調査対象となった臨床試験施設の約30.0%は、新たな臨床試験への患者のリクルートだけでなく、既に登録されている患者を試験スケジュールに従わせることにも大きな影響を与えると予測されています。また、欧州の治験実施施設の81％、米国の治験実施施設の56.0％が、患者が治験への参加を継続する可能性が低いと回答しています。バーチャルな方法は、患者が自宅から試験に参加できるため、訪問が不可能な場合でも調査を継続することができ、臨床試験参加者から安全性と有効性のデータを収集する新しいアプローチとなります。

セグメント別展望

世界のバーチャル臨床試験市場において腫瘍分野が大きなシェアを占める

適応症別では、がん領域が世界市場で大きなシェアを占めています。2021年7月に更新された国際がん研究機関（IARC）の推計によると、2040年までにがんの世界の負担は2,750万人に増加し、1,630万人が死亡すると予測されています。

バーチャル臨床試験は、がん患者のリスクを最小化し、対面式の臨床試験訪問に費やす時間を短縮します。患者の安全を守るため、がん臨床試験の治験責任医師やスポンサーは、バーチャル臨床試験や遠隔臨床試験を急速に取り入れています。このような市場開拓は、この市場セグメントの成長にさらに貢献しています。National Clinical Trialsによると、2020年4月には、さまざまな開発段階にわたるがん領域の臨床試験が約8,306件実施されました。

地域別展望

世界のバーチャル臨床試験市場は、北米（米国とカナダ）、欧州（イタリア、スペイン、ドイツ、フランス、その他）、アジア太平洋（インド、中国、日本、韓国、その他）、世界のその他の中東・アフリカ（中東およびアフリカ、ラテンアメリカ）の地域別にさらに細分化されています。すべての地域の中で、アジア太平洋は予測期間中に最も高いCAGRを示すと予想されています。同地域の成長の背景には、同地域全域でデジタル技術の浸透が進むとともに、候補者を容易に採用できるようになった大規模な患者プールの増加があります。例えば、2022年10月、OracleとObvioHealthは、アジア太平洋における仮想/分散型臨床試験に多様なデータセットを統合するための戦略的提携を締結しました。この取り組みにより、機器、患者、施設から収集したマルチソースデータの迅速な収集、統合、分析が可能になると予想されます。主要企業のこうした活動は、この地域の市場成長にさらに貢献しています。

バーチャル臨床試験の世界市場で北米が大きなシェアを占める

製薬企業の研究開発数の増加、臨床研究における新技術の採用の増加、および政府の一貫した政策が、この地域の市場成長を促進する顕著な要因のいくつかです。例えば、2023年4月、オーガニック乳児用調製粉乳のBobbie社は、初のバーチャル臨床試験を発表し、科学に裏打ちされたこのブランドは、アメリカの両親のために、研究、革新、ユニークな製品やレシピを倍増させることを可能にしました。最初の患者は、新しい乳児用調製粉乳の成長、耐性、安全性を評価するための試験に登録されました。

Parexelは、ハイブリッド・アプローチやバーチャル・アプローチを含む100以上の分散型試験を実施しました。また、Covanceは、米国内に約1,900のLabCorp Patient Service Centersを持ち、患者に臨床試験を提供しています。地域全体の主要企業によるこのような市場開拓は、地域市場の成長にさらに貢献しています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリスト洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • ICON PLC
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings（Covance Inc.）
  • Oracle Corp.
  • Parexel International Corp.
  • 主要戦略分析

第4章 市場セグメンテーション

  • バーチャル臨床試験の世界市場：試験設計別
    • 介入試験
    • 観察試験
    • 拡大アクセス
  • バーチャル臨床試験の世界市場：適応症別
    • 心血管疾患
    • がん
    • その他（眼科、感染症、その他）

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 世界のその他の中東・アフリカ

第6章 企業プロファイル

  • Biorasi
  • Clara Health
  • Clariness
  • Clinical Ink Inc.
  • CRF Health
  • Dassault Systemes SE（Medidata Solutions Inc.）
  • Halo Health System Inc.
  • ICON PLC
  • LEO Innovation Lab
  • Medable Inc.
  • Medpace Holdings Inc.
  • PRA Health Sciences
  • Signant Health
  • TrialBee Inc.
  • Worldwide Clinical Trials
図表

LIST OF TABLES

  • 1. GLOBAL VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
  • 2. GLOBAL INTERVENTIONAL VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL OBSERVATIONAL VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL EXPANDED ACCESS VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 6. GLOBAL VIRTUAL CLINICAL TRIALS FOR CARDIOVASCULAR DISEASES (CVDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL VIRTUAL CLINICAL TRIALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL VIRTUAL CLINICAL TRIALS FOR OTHER INDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. NORTH AMERICAN VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
  • 12. NORTH AMERICAN VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 13. EUROPEAN VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 14. EUROPEAN VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
  • 15. EUROPEAN VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 16. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
  • 18. ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 19. REST OF THE WORLD VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD VIRTUAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE BY STUDY DESIGN, 2022 VS 2030 (%)
  • 2. GLOBAL INTERVENTIONAL VIRTUAL CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL OBSERVATIONAL VIRTUAL CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL EXPANDED ACCESS VIRTUAL CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE BY INDICATION, 2022 VS 2030 (%)
  • 6. GLOBAL VIRTUAL CLINICAL TRIALS FOR CARDIOVASCULAR DISEASES (CVDS) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL VIRTUAL CLINICAL TRIALS FOR ONCOLOGY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL VIRTUAL CLINICAL TRIALS FOR OTHER INDICATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL VIRTUAL CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. US VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. CANADA VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. UK VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. FRANCE VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. GERMANY VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. ITALY VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. SPAIN VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. REST OF EUROPE VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. INDIA VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CHINA VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. JAPAN VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SOUTH KOREA VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF ASIA-PACIFIC VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF THE WORLD VIRTUAL CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027842

Title: Global Virtual Clinical Trials Market Size, Share & Trends Analysis Report by Study Design (Observational, Interventional, and Expanded Access), and by Indication (Cardiovascular Diseases (CVDs), Oncology, and Others)Forecast Period (2023-2030).

The global virtual clinical trials market is anticipated to grow at a considerable CAGR of 8.5% during the forecast period. The rise in R&D activities, increasing healthcare digitization, as well as the adoption of telehealth are the key factors driving the growth of the global market. The alliances between clinical research organizations, pharmaceutical, and biotechnology companies as well as cohesive government initiatives are further contributing to the market development.

As per the continuum clinical report published in April 2020, approximately 30.0% of the surveyed clinical trial places are projected to have a huge impact on recruiting patients for new trial studies as well as retaining already-enrolled patients compliant with their study schedules. Also, 81% of the European clinical trial study sites and 56.0% of the US sites indicated that the patients are less likely to continue participating in studies. A virtual method lets people take part in the trial from their homes ensuring research can continue even when site visits cannot, hence, representing a novel approach of collecting safety and efficacy data from participants of clinical studies.

Segmental Outlook

The global virtual clinical trials market is segmented based on study design and indication. Based on study design, the market is segmented into observational, interventional, and expanded access. Based on indication, the market is segmented into cardiovascular disease, oncology, and other indication types (ophthalmology, infectious disease, and other).

Oncology Held Considerable Share in Global Virtual clinical trials Market

The oncology segment held considerable share in the global market based on indication type. The rising cancer prevalence, increasing government initiatives for cancer awareness and increasing R&D activities on the development of cancer drugs has increased the number of oncological trials. according to estimates from the International Agency for Research on Cancer (IARC) updates from July 2021, by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide.

Virtual clinical trials minimize the cancer patient's risk and decrease time spent on face-to-face trial visits. To keep patients safe, oncology clinical trial investigators and sponsors have quickly incorporated virtual and remote trials. Such developments are further contributing to the growth of this market segment. According to the National Clinical Trials, in April 2020, around 8,306 clinical trials on oncology across the various phases of development were conducted.

Regional Outlook

The global virtual clinical trials market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among all the regions, the Asia-Pacific region is anticipated to exhibit highest CAGR during the forecast period. The regional growth is attributed to the increasing availability of a large patient pool enabling easy recruitment of candidates along with enhanced penetration of digital technologies across the region. For instance, in October 2022, Oracle and ObvioHealth entered into a strategic collaboration to integrate diverse data sets into virtual/decentralized clinical trials in the Asia-Pacific region. This initiative is anticipated to allow the quick collection, integration and analysis of multi-source data collected from devices, patients, and sites. Such activities of key players are further contributing to the regional market growth.

North America Held Considerable Share in the Global Virtual Clinical Trials Market

The increasing number of pharmaceutical R&D, increasing adoption of new technologies in clinical research as well as cohesive government policies are some of the prominent factors driving the regional market growth. For instance, in April 2023, Bobbie, the organic infant formula company announced its first virtual clinical trial, enabling the science-backed brand to double down on research, innovation and unique products and recipes for American parents. The first patient was enrolled for a study designed to evaluate the growth, tolerance, and safety of a new infant formula.

Parexel performed more than 100 decentralized trials including hybrid and virtual approaches. Covance also has around 1,900 LabCorp Patient Service Centers across the US that brings the trial to patients. Such development by key players across the region is further contributing to the growth of the regional market growth.

Market Players Outlook

The major companies serving the global virtual clinical trials market include: ICON PLC, Laboratory Corporation of America Holdings (Covance Inc.), Oracle Corp., Parexel International Corp., IQVIA Holdings Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2022, Signant Health introduced telemedicine platform innovations to optimize virtual and remote clinical trial operations.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global virtual clinical trials market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. ICON PLC
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. IQVIA Holdings Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Laboratory Corporation of America Holdings (Covance Inc.)
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Oracle Corp.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Parexel International Corp.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Virtual Clinical Trials Market by Study Design
    • 4.1.1. Interventional
    • 4.1.2. Observational
    • 4.1.3. Expanded Access
  • 4.2. Global Virtual Clinical Trials Market by Indication
    • 4.2.1. Cardiovascular Diseases
    • 4.2.2. Oncology
    • 4.2.3. Other (Ophthalmology, Infectious Disease, and other)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Biorasi
  • 6.2. Clara Health
  • 6.3. Clariness
  • 6.4. Clinical Ink Inc.
  • 6.5. CRF Health
  • 6.6. Dassault Systemes SE (Medidata Solutions Inc.)
  • 6.7. Halo Health System Inc.
  • 6.8. ICON PLC
  • 6.9. LEO Innovation Lab
  • 6.10. Medable Inc.
  • 6.11. Medpace Holdings Inc.
  • 6.12. PRA Health Sciences
  • 6.13. Signant Health
  • 6.14. TrialBee Inc.
  • 6.15. Worldwide Clinical Trials